Nielsen, Mette S. http://orcid.org/0000-0001-7354-4648
Christensen, Bodil J. http://orcid.org/0000-0003-4529-8253
Ritz, Christian http://orcid.org/0000-0002-5095-0624
Holm, Lotte http://orcid.org/0000-0003-0667-7779
Lunn, Susanne http://orcid.org/0000-0002-6812-1867
Tækker, Louise http://orcid.org/0000-0003-0363-6090
Schmidt, Julie Berg http://orcid.org/0000-0002-0299-7874
Bredie, Wender L. P. http://orcid.org/0000-0001-5145-4131
Wewer Albrechtsen, Nicolai J. http://orcid.org/0000-0003-4230-5753
Holst, Jens J. http://orcid.org/0000-0001-6853-3805
Hilbert, Anja http://orcid.org/0000-0003-2775-1296
le Roux, Carel W. http://orcid.org/0000-0001-5521-5445
Sjödin, Anders http://orcid.org/0000-0002-6451-3847
Article History
Received: 29 October 2020
Revised: 12 March 2021
Accepted: 22 March 2021
First Online: 30 March 2021
Declarations
:
: All procedures performed in the study were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all participants included in the study.
: CWlR is supported by grants from Science Foundation Ireland (ref CitationRef removed/YI/B2480), Health Research Board (USIRL-2016-2) and the Irish Research Council during the conduct of the study. Furthermore, CWlR reported being on the advisory boards for Novo Nordisk and GI Dynamics, receiving a research grant from AnaBio, receiving honoraria for lectures and advisory work from Eli Lily, Johnson and Johnson, Sanofi Aventis, Astra Zeneca, Janssen, Bristol-Myers Squibb and Boehringer-Ingelheim, and reported shares in Keyron. AH was funded by the German Federal Ministry of Education and Research, grant 01EO1501. JJH reported being on the advisory board for Novo Nordisk and MSD. The other authors declared competing interests.